

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Comparison of therapeutic effects of 5% minoxidil solution alone with the combination of 5% minoxidil and flutamide solution in patients with androgenic alopecia

#### Protocol summary

##### Study aim

Comparison of therapeutic effects of minoxidil solution alone with the combination of minoxidil and flutamide solution in patients with androgenetic alopecia

##### Design

A randomized double-blinding clinical trial, with the parallel groups

##### Settings and conduct

In this study, 40 patients with androgenic alopecia will be included and will be randomly divided into two groups. Minoxidil solution will be used in one group and flutamide and minoxidil solution in the other group. Then the severity of hair loss and hair density of patients are evaluated.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria included the diagnosis of androgenic alopecia by two experienced dermatologists based on Hamilton diagnostic criteria, severity of hair loss in stages 2 to 5 according to Hamilton scale and in stages 1 and 2 according to Ludwig scale, hair loss less than 10 years and patient satisfaction to participate in the study. Exclusion criteria include a history or observation of allergies to any of the minoxidil and flutamide drugs, a history of heart disease and taking antihypertensive drugs, receiving systemic treatment for androgenic alopecia during the 6 months prior to the study, and other types of alopecia, such as Alopecia areata, telogen effluvium, anagen effluvium, and scarring alopecia and any systemic skin disease, and being pregnant or lactating, or postmenopausal women.

##### Intervention groups

In this study, patients in the first intervention group will receive 1 cc (equivalent to 20 drops) of 5% minoxidil solution twice a day and patients in the second intervention group will receive 1 cc (equivalent to 20 drops) of 2% flutamide + 5% minoxidil solution twice a day. Patients in both groups will take the solutions for 9

months.

##### Main outcome variables

Hair density; Severity of hair loss

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20200825048515N6**

Registration date: **2020-10-07, 1399/07/16**

Registration timing: **prospective**

Last update: **2020-10-07, 1399/07/16**

Update count: **0**

##### Registration date

2020-10-07, 1399/07/16

##### Registrant information

##### Name

Asieh Maghami Mehr

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 0000 0000

##### Email address

asimaghami@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-10-22, 1399/08/01

##### Expected recruitment end date

2021-04-19, 1400/01/30

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison of therapeutic effects of 5% minoxidil solution alone with the combination of 5% minoxidil and flutamide solution in patients with androgenic alopecia

**Public title**

Comparison of the therapeutic effects of minoxidil solution alone with the combination of minoxidil and flutamide solution in patients with androgenic alopecia

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Confirmation of androgenic alopecia by two experienced dermatologists based on Hamilton diagnostic criteria  
Patient consent to participate in the study  
The intensity of hair loss in stage 2 to 5 according to Hamilton scale and in stages 1 and 2 according to Ludwig scale  
The duration of hair loss is less than 10 years

**Exclusion criteria:**

History or observation of allergies to any of the drugs minoxidil and flutamide  
History of heart disease and use of antihypertensive drugs  
Receiving systemic treatment for androgenic alopecia during the 6 months prior to the study  
Other types of alopecia such as alopecia areata, telogen effluvium, anagen effluvium and scarring alopecia of any systemic cutaneous disease

**Age**

From **18 years** old to **45 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Investigator

**Sample size**

Target sample size: **40**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

40 eligible patients will be randomly selected. Then, these patients will be randomly encoded using computer software called "Random Allocation" and automatically divided into two groups. The relevant codes will be entered in the raw checklists and each of these checklists will be randomly assigned to one patient and that patient will be randomly assigned to one of the two study groups.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The two solutions of minoxidil and the combined solution of flutamide and minoxidil are already prepared by the pharmacist in the same volume and with the same color and shape, and are labeled A and B and will be given to

the patients. Therefore, the patient and the researcher will not have any information about the two prescribed solutions.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Isfahan University of Medical Sciences

**Street address**

Hezar Jarib Ave, Azadi Square.

**City**

Isfaha

**Province**

Isfahan

**Postal code**

8174673461

**Approval date**

2019-07-03, 1398/04/12

**Ethics committee reference number**

IR.MUI.MED.REC.1398.562

**Health conditions studied****1****Description of health condition studied**

Androgenic alopecia

**ICD-10 code**

L64.9

**ICD-10 code description**

Androgenic alopecia, unspecified

**Primary outcomes****1****Description**

Hair density

**Timepoint**

Pre-and post-intervention

**Method of measurement**

Hair polarizer

**2****Description**

Severity of hair loss

**Timepoint**

Pre-and post-intervention

## Method of measurement

By a skilled physician based on Hamilton-Norwood scale for male pattern hair loss and Ludwig scale for female pattern hair loss

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Patients in the first intervention group will take 1 cc (equivalent to 20 drops) of 5% minoxidil solution twice a day for 9 months.

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group: Patients in the second intervention group will take 1 cc (equivalent to 20 drops) of the combined solution of 2% flutamide and 5% minoxidil twice a day for 9 months.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Al-Zahra Hospital

##### Full name of responsible person

Gita Faghihi

##### Street address

Soffe Blvd, Isfahan

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8174675731

##### Phone

+98 31 3620 2020

##### Email

g\_faghighi@med.mui.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Esfahan University of Medical Sciences

##### Full name of responsible person

Shaghayegh Haghjoo Javanmard

##### Street address

Vice Chancellor for Research, School of Medicine,  
Hezar Jarib Street, Isfahan.

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8174673461

##### Phone

+98 31 3668 8597

##### Email

dean@med.mui.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

No

#### Title of funding source

Isfahan University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Esfahan University of Medical Sciences

##### Full name of responsible person

Gita Faghihi

##### Position

Professor

##### Latest degree

Specialist

##### Other areas of specialty/work

Dermatology

##### Street address

Dermatology Department, Al-Zahra Hospital, Hezar Jarib Street

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8174675731

##### Phone

+98 31 3620 2020

##### Email

g\_faghighi@med.mui.ac.ir

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Gita Faghihi

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dermatology

**Street address**

Dermatology Department, Al-Zahra Hospital, Hezar Jarib Street

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174675731

**Phone**

+98 31 3620 2020

**Email**

g\_faghihi@med.mui.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Maedeh Sadat Hosseini

**Position**

Non-faculty physician

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Dermatology

**Street address**

Robat Street

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8139946553

**Phone**

+98 31 3442 7529

**Email**

maedeh.hosseini71@yahoo.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available